United States Primary Sclerosing Cholangitis Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Primary Sclerosing Cholangitis market is expected to reach at a Significant CAGR during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ In August 2025, Critical Path Institute's Translational Therapeutics Accelerator awarded a $473,000 grant to Amsterdam UMC for developing a novel small molecule therapy targeting PSC.

✅ In July 2025, Chemomab Therapeutics presented positive Phase 2 SPRING trial data for nebokitug (CM-101), showing significant improvements in fibrotic and inflammatory biomarkers in PSC patients.

✅ In April 2025, Esperion unveiled promising research supporting lead development candidates for PSC, including ESP-1336, novel allosteric inhibitors targeting hepatic inflammation and fibrosis.

Japan: Recent Industry Developments

✅ In May 2025, Zydus Therapeutics reported successful Phase 3 clinical trial outcomes for Saroglitazar in Primary Biliary Cholangitis (PBC), with plans to file for U.S. regulatory approval in 2026.

✅ In July 2024, a groundbreaking trial began where a patient received weekly faecal microbiota transplantation (FMT) to treat PSC and inflammatory bowel disease, marking a world-first approach in PSC treatment.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/primary-sclerosing-cholangitis-market?sb

Recent Mergers and Acquisitions:

United States: Recent M&A Developments in PSC

✅ In April 2025, Gilead Sciences acquired CymaBay Therapeutics for $4.3 billion, gaining access to seladelpar, an oral PPARδ agonist in Phase III trials for Primary Biliary Cholangitis (PBC), a condition related to PSC. This acquisition bolsters Gilead's hepatology portfolio.

✅ In January 2025, Johnson & Johnson completed a $14.6 billion acquisition of Intra-Cellular Therapies, focusing on expanding its neurology and psychiatry divisions. While not directly related to PSC, this strategic move reflects J&J's broader interest in rare disease treatments.

✅ In January 2025, Eli Lilly announced the acquisition of a promising liver disease drug from Boston Pharmaceuticals for up to $2 billion, aiming to enhance its hepatology pipeline and address liver-related conditions, including PSC.

Japan: Recent M&A Developments in PSC

✅ In July 2025, Zydus Therapeutics, a division of Zydus Lifesciences, reported successful Phase 3 clinical trial outcomes for Saroglitazar in Primary Biliary Cholangitis (PBC), a condition related to PSC. While this is a clinical development rather than an acquisition, it signifies Zydus's commitment to expanding its liver disease portfolio.

Key Players:

=> Intercept Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Allergan, Genfit, Pliant Therapeutics, ChemomAb Therapeutics Ltd., and Dr. Falk Pharma among others.

Growth Forecast Projected:

The Global Primary Sclerosing Cholangitis Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Primary Sclerosing Cholangitis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=primary-sclerosing-cholangitis-market

Key Segments:

➥ By Treatment: Medication-based Therapies, Bile Duct Blockages, Liver Transplantation

➥ By Disease Stage: Early-stage PSC, Moderate-stage PSC, Advanced-stage PSC

➥ By Patient Age: Child (0-18), Adult (18 and above)

➥ By End-User: Hospitals, Specialty Clinics, Others

Regional Analysis for Primary Sclerosing Cholangitis Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Primary Sclerosing Cholangitis producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Primary Sclerosing Cholangitis revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/primary-sclerosing-cholangitis-market?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us
-

Company
Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.